AKYA
Akoya Biosciences, Inc. [AKYA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AKYA Stock Summary
Top 10 Correlated ETFs
AKYA
Top 10 Correlated Stocks
AKYA
In the News
Akoya Biosciences, Inc. (AKYA) Q4 2023 Earnings Call Transcript
Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants Subbu Nambi - Guggenheim Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley John Sourbeer - UBS Mark Massaro - BTIG Rachel Vatnsdal - JP Morgan Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Fourth Quarter 2023 Earnings Conference Call.
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.50 per share a year ago.
Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
MARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on March 4th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?
Akoya (AKYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
5 Small-Cap Stocks to Play the January Effect
Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
Best Momentum Stocks to Buy for January 8th
AKYA, DRTS and TRUP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.
New Strong Buy Stocks for January 8th
TIMB, AKYA, DRTS, TRUP and QSG have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.
How Akoya Biosciences (AKYA) Stock Stands Out in a Strong Industry
Akoya Biosciences (AKYA) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
How Much Upside is Left in Akoya (AKYA)? Wall Street Analysts Think 86%
The average of price targets set by Wall Street analysts indicates a potential upside of 86% in Akoya (AKYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Akoya Biosciences, Inc. (AKYA) Q3 2023 Earnings Call Transcript
Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Priyam Shah - Head of Investor Relations Brian McKelligon - Chief Executive Officer Johnny Ek - Chief Financial Officer Conference Call Participants Edmund Tu - Morgan Stanley Kyle Mikson - Canaccord Genuity Timothy Chiang - Capital One Mason Carrico - Stephens Inc. Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Akoya Biosciences Incorporated Third Quarter 2023 Earnings Conference Call.
AKYA Financial details
AKYA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.14 | 1.14 | 1.47 | 1.98 | 2.17 | |
| Net income per share | -0.4 | -0.45 | -1.15 | -1.87 | -1.43 | |
| Operating cash flow per share | -0.37 | -0.18 | -0.96 | -1.42 | -1.15 | |
| Free cash flow per share | -0.45 | -0.27 | -1.1 | -1.61 | -1.23 | |
| Cash per share | 0.58 | 0.46 | 3.02 | 2.15 | 1.87 | |
| Book value per share | -0.81 | 0.5 | 3.24 | 1.55 | 1.21 | |
| Tangible book value per share | -1.96 | -0.6 | 2.19 | 0.54 | 0.41 | |
| Share holders equity per share | -0.81 | 0.5 | 3.24 | 1.55 | 1.21 | |
| Interest debt per share | 0.72 | 1.02 | 0.96 | 2.13 | 1.97 | |
| Market cap | 742.21M | 742.21M | 572.96M | 361.24M | 216.84M | |
| Enterprise value | 755.33M | 760.2M | 492.35M | 362.79M | 219.42M | |
| P/E ratio | -50.32 | -44.43 | -13.34 | -5.11 | -3.42 | |
| Price to sales ratio | 17.57 | 17.49 | 10.43 | 4.83 | 2.24 | |
| POCF ratio | -53.88 | -108.46 | -15.89 | -6.75 | -4.26 | |
| PFCF ratio | -44.59 | -73.21 | -13.92 | -5.94 | -3.97 | |
| P/B Ratio | -24.61 | 39.97 | 4.72 | 6.17 | 4.03 | |
| PTB ratio | -24.61 | 39.97 | 4.72 | 6.17 | 4.03 | |
| EV to sales | 17.88 | 17.91 | 8.97 | 4.85 | 2.27 | |
| Enterprise value over EBITDA | -69.8 | -99.53 | -14.96 | -6.11 | -4.65 | |
| EV to operating cash flow | -54.83 | -111.09 | -13.65 | -6.78 | -4.31 | |
| EV to free cash flow | -45.38 | -74.99 | -11.96 | -5.96 | -4.02 | |
| Earnings yield | -0.02 | -0.02 | -0.07 | -0.2 | -0.29 | |
| Free cash flow yield | -0.02 | -0.01 | -0.07 | -0.17 | -0.25 | |
| Debt to equity | -0.82 | 1.88 | 0.27 | 1.29 | 1.46 | |
| Debt to assets | 0.28 | 0.45 | 0.17 | 0.43 | 0.44 | |
| Net debt to EBITDA | -1.21 | -2.36 | 2.45 | -0.03 | -0.05 | |
| Current ratio | 1.93 | 1.67 | 5.09 | 3.03 | 3.45 | |
| Interest coverage | -7.18 | -4.22 | -11.95 | -14.54 | -6.4 | |
| Income quality | 0.93 | 0.41 | 0.84 | 0.76 | 0.8 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | -0.03 | 0 | 0 | |
| Sales general and administrative to revenue | 0.6 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.21 | 0.23 | 0.29 | 0.31 | 0.23 | |
| Intangibles to total assets | 0.47 | 0.53 | 0.21 | 0.22 | 0.2 | |
| Capex to operating cash flow | 0.21 | 0.48 | 0.14 | 0.14 | 0.07 | |
| Capex to revenue | -0.07 | -0.08 | -0.09 | -0.1 | -0.04 | |
| Capex to depreciation | -0.94 | -0.86 | -1.06 | -1.03 | -0.41 | |
| Stock based compensation to revenue | 0 | 0.01 | 0.07 | 0.1 | 0.11 | |
| Graham number | 2.7 | 2.25 | 9.15 | 8.08 | 6.23 | |
| ROIC | 2.67 | -0.21 | -0.24 | -0.45 | -0.4 | |
| Return on tangible assets | -0.31 | -0.46 | -0.28 | -0.51 | -0.44 | |
| Graham Net | -2.32 | -0.95 | 1.47 | -0.57 | -0.49 | |
| Working capital | 19.72M | 11.53M | 113.13M | 75.14M | 86.45M | |
| Tangible asset value | -72.56M | -22.41M | 81.94M | 20.27M | 18.1M | |
| Net current asset value | -78.7M | -30.39M | 71.26M | -5.25M | -4.81M | |
| Invested capital | -0.82 | 1.88 | 0.27 | 1.29 | 1.46 | |
| Average receivables | 0 | 9.82M | 7.96M | 9.59M | 13.36M | |
| Average payables | 0 | 6.6M | 14.14M | 25.17M | 19.46M | |
| Average inventory | 0 | 4.18M | 6.64M | 11.75M | 16.18M | |
| Days sales outstanding | 113.79 | 55.64 | 62.77 | 47.44 | 64.19 | |
| Days payables outstanding | 168.64 | 112.01 | 409.07 | 314.87 | 88.82 | |
| Days of inventory on hand | 85.01 | 94.1 | 158.95 | 168.02 | 134.83 | |
| Receivables turnover | 3.21 | 6.56 | 5.82 | 7.69 | 5.69 | |
| Payables turnover | 2.16 | 3.26 | 0.89 | 1.16 | 4.11 | |
| Inventory turnover | 4.29 | 3.88 | 2.3 | 2.17 | 2.71 | |
| ROE | 0.49 | -0.9 | -0.35 | -1.21 | -1.18 | |
| Capex per share | -0.08 | -0.09 | -0.14 | -0.19 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.56 | 0.56 | 0.58 | 0.51 | 0.54 | |
| Net income per share | -0.5 | -0.49 | -0.51 | -0.26 | -0.22 | |
| Operating cash flow per share | -0.26 | -0.52 | -0.29 | -0.28 | -0.11 | |
| Free cash flow per share | -0.29 | -0.54 | -0.33 | -0.3 | -0.13 | |
| Cash per share | 2.14 | 1.57 | 2.3 | 1.6 | 1.69 | |
| Book value per share | 1.54 | 1.1 | 1.77 | 1.27 | 1.1 | |
| Tangible book value per share | 0.53 | 0.11 | 0.85 | 0.52 | 0.37 | |
| Share holders equity per share | 1.54 | 1.1 | 1.77 | 1.27 | 1.1 | |
| Interest debt per share | 2.04 | 2.02 | 1.92 | 1.49 | 1.65 | |
| Market cap | 363.68M | 313.51M | 300.33M | 227.74M | 239.56M | |
| Enterprise value | 365.24M | 328.53M | 282.67M | 224.21M | 242.14M | |
| P/E ratio | -4.82 | -4.17 | -3.61 | -4.41 | -5.54 | |
| Price to sales ratio | 17.14 | 14.64 | 12.77 | 9.03 | 9.04 | |
| POCF ratio | -36.34 | -15.87 | -25.44 | -16.56 | -43.16 | |
| PFCF ratio | -33.44 | -15.25 | -22.71 | -15.61 | -38.98 | |
| P/B Ratio | 6.21 | 7.44 | 4.18 | 3.67 | 4.46 | |
| PTB ratio | 6.21 | 7.44 | 4.18 | 3.67 | 4.46 | |
| EV to sales | 17.21 | 15.34 | 12.02 | 8.89 | 9.14 | |
| Enterprise value over EBITDA | -24.68 | -22.62 | -17.41 | -17.52 | -36.05 | |
| EV to operating cash flow | -36.5 | -16.63 | -23.95 | -16.3 | -43.62 | |
| EV to free cash flow | -33.58 | -15.98 | -21.37 | -15.37 | -39.4 | |
| Earnings yield | -0.05 | -0.06 | -0.07 | -0.06 | -0.05 | |
| Free cash flow yield | -0.03 | -0.07 | -0.04 | -0.06 | -0.03 | |
| Debt to equity | 1.29 | 1.79 | 1.05 | 1.21 | 1.46 | |
| Debt to assets | 0.43 | 0.49 | 0.4 | 0.42 | 0.44 | |
| Net debt to EBITDA | -0.11 | -1.03 | 1.09 | 0.28 | -0.38 | |
| Current ratio | 3.03 | 2.76 | 3.37 | 3.29 | 3.45 | |
| Interest coverage | -9.26 | -8.38 | -8.85 | 5.16 | -3.85 | |
| Income quality | 0.53 | 1.05 | 0.57 | 1.06 | 0.51 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.3 | 0.27 | 0.27 | 0.21 | 0.18 | |
| Intangibles to total assets | 0.22 | 0.24 | 0.2 | 0.21 | 0.2 | |
| Capex to operating cash flow | 0.09 | 0.04 | 0.12 | 0.06 | 0.11 | |
| Capex to revenue | -0.04 | -0.04 | -0.06 | -0.03 | -0.02 | |
| Capex to depreciation | -0.46 | -0.38 | -0.68 | -0.32 | -0.28 | |
| Stock based compensation to revenue | 0.1 | 0.11 | 0.11 | 0.11 | 0.1 | |
| Graham number | 4.15 | 3.48 | 4.51 | 2.74 | 2.33 | |
| ROIC | -0.12 | -0.13 | -0.12 | -0.08 | -0.06 | |
| Return on tangible assets | -0.14 | -0.16 | -0.14 | -0.09 | -0.07 | |
| Graham Net | -0.57 | -0.91 | -0.15 | -0.31 | -0.44 | |
| Working capital | 75.14M | 58.45M | 88.78M | 81.43M | 86.45M | |
| Tangible asset value | 20.27M | 4.37M | 34.51M | 25.59M | 18.1M | |
| Net current asset value | -5.25M | -20.5M | 9.19M | 1.68M | -4.81M | |
| Invested capital | 1.29 | 1.79 | 1.05 | 1.21 | 1.46 | |
| Average receivables | 9.2M | 11.34M | 12.9M | 14.48M | 16.55M | |
| Average payables | 24.68M | 25.07M | 24.72M | 25.77M | 18.43M | |
| Average inventory | 13.77M | 14.5M | 15.32M | 17.44M | 18.31M | |
| Days sales outstanding | 41.27 | 54.41 | 49.23 | 57.45 | 57.74 | |
| Days payables outstanding | 266.35 | 226.88 | 208.8 | 227.14 | 90.27 | |
| Days of inventory on hand | 142.13 | 143.21 | 127.29 | 169.8 | 137.04 | |
| Receivables turnover | 2.18 | 1.65 | 1.83 | 1.57 | 1.56 | |
| Payables turnover | 0.34 | 0.4 | 0.43 | 0.4 | 1 | |
| Inventory turnover | 0.63 | 0.63 | 0.71 | 0.53 | 0.66 | |
| ROE | -0.32 | -0.45 | -0.29 | -0.21 | -0.2 | |
| Capex per share | -0.02 | -0.02 | -0.04 | -0.02 | -0.01 |
AKYA Frequently Asked Questions
What is Akoya Biosciences, Inc. stock symbol ?
Akoya Biosciences, Inc. is a US stock , located in Marlborough of Ma and trading under the symbol AKYA
What is Akoya Biosciences, Inc. stock quote today ?
Akoya Biosciences, Inc. stock price is $4.01 today.
Is Akoya Biosciences, Inc. stock public?
Yes, Akoya Biosciences, Inc. is a publicly traded company.
Company Profile
- Volume Average 189.2K
- Market Capitalization 202.95M
- Employee 330
- CEO Mr. Brian McKelligon
- Headquarters Marlborough,MA,US
- IPO Date 2021-04-16
-
Website
https://www.akoyabio.com 
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
